M&A Deal Summary

EUSA Pharma Acquires Apeiron Biologics AG - Isqette

On October 4, 2016, EUSA Pharma acquired life science company Apeiron Biologics AG - Isqette from Apeiron Biologics

Acquisition Highlights
  • This is EUSA Pharma’s 1st transaction in the Life Science sector.
  • This is EUSA Pharma’s 1st transaction in the United States.
  • This is EUSA Pharma’s 1st transaction in Pennsylvania.

M&A Deal Summary
Date 2016-10-04
Target Apeiron Biologics AG - Isqette
Sector Life Science
Buyer(s) EUSA Pharma
Sellers(s) Apeiron Biologics
Deal Type Divestiture

Target

Apeiron Biologics AG - Isqette

Langhorne, Pennsylvania, United States
Apeiron Biologics AG - Isqette (Dinutuximab Beta) is an immunotherapy has orphan drug designation in the US and EU and is currently under review for marketing authorization by the EMA.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

EUSA Pharma

Langhorne, Pennsylvania, United States
Category Company
Founded 2006
Sector Life Science
DESCRIPTION

EUSA Pharma is a trans-Atlantic specialty pharmaceutical company focused on oncology and critical care. EUSA intends to build a portfolio of products that are on the market or in late-stage clinical trials through acquisitions and in-licensing. The company has a sales and marketing organization and commercial infrastructure in the US and all major European countries.

DEAL STATS #
Overall 1 of 2
Sector (Life Science) 1 of 2
Type (Divestiture) 1 of 2
State (Pennsylvania) 1 of 1
Country (United States) 1 of 2
Year (2016) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-07-18 SYLVANT

United States

SYLVANT is approved in more than 40 countries worldwide, including the United States, the European Union, the Republic of Korea and Canada, for the treatment of idiopathic multicentric Castleman’s disease (iMCD), a rare, life threatening and debilitating orphan condition. Idiopathic MCD is an inflammatory lymphoproliferative disorder, which causes the abnormal overgrowth of immune cells and shares many symptomatic and histological features with lymphoma.1 The disease can affect individuals at any age, with iMCD representing one-third to half of all multicentric Castleman’s disease (MCD).

Buy $115M

Seller(S) 1

SELLER

Apeiron Biologics

Vienna, Austria
Category Company
Founded 2006
Sector Life Science
Employees35
DESCRIPTION

Apeiron Biologics is a private biopharmaceutical company that co-developed QARZIBA (dinutuximab beta), a high-risk neuroblastoma drug, which it licensed to EUSA Pharma (UK) Limited (now a Recordati S.p.A. company) in 2016. The company also maintains a portfolio of more than 400 patents including the intellectual property and licenses for an early-stage immuno-oncology portfolio currently being developed by invIOs Holding AG which was spun-off from APEIRON in 2022. Apeiron Biologics was formed in 2000 and is based in

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (Pennsylvania) 1 of 1
Country (United States) 1 of 1
Year (2016) 1 of 1
Mergr

Product

Company

Legal